Hong Kong Logistics Stock News

CICC recently maintained its Buy rating on JD Health International, Inc. and reiterated confidence in the company following a quarter of strong year-over-year revenue and profit growth. This combination of upbeat analyst commentary and improved financial performance has reinforced investor attention on JD Health’s position in China’s online healthcare market. Now, we’ll explore how this stronger quarterly performance may influence JD Health’s existing investment narrative built around...

CNOOC (SEHK:883) has reported first oil from the Buzios6 Project in Brazil’s pre salt Buzios field, a large deep water development that lifts the oilfield’s installed capacity to 1.15 million barrels per day. See our latest analysis for CNOOC. Despite the Buzios6 milestone and recent board changes in late December, CNOOC’s HK$20.94 share price sits after a mixed patch, with a 1 day share price return of 1.26% but a 7 day share price return decline of 4.21%, while the 90 day share price return...

MMG (SEHK:1208) has moved ahead with a major expansion of its Khoemacau Copper Mine in Botswana, committing about US$900 million to increase output capacity and target lower operating costs. See our latest analysis for MMG. That expansion decision comes after a strong run in the stock, with a 30 day share price return of 11.71% and a 90 day share price return of 31.69%, alongside a very large 1 year total shareholder return that points to momentum still building rather than fading. If MMG’s...

Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies. See our latest analysis for Ascentage Pharma Group International. The FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...

Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906. See our latest analysis for Sino Biopharmaceutical. The latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...

In December 2025, PCCW Interactive Media Holdings Limited, a subsidiary of PCCW, entered into a Branding and Marketing Arrangements Framework Agreement with FWD Life Insurance covering 1 January 2026 to 31 December 2028, under which PCCW Group (including the HKT Group) will provide branding, spokesperson and marketing services charged at market-referenced rates. The agreement is grounded in arm’s length annual caps informed by historical IFRS-recognised service revenues of about US$6.60...

DPC Dash (SEHK:1405), the exclusive Domino’s Pizza franchisee in China, hit its full year store opening target with 1,315 outlets across 60 cities and loyalty membership reaching 35.6 million, highlighting recent operational momentum. See our latest analysis for DPC Dash. Despite the recent operational progress, the share price has been under pressure, with a 30 day share price return of an 8.43% decline and a 90 day share price return of an 18.92% decline, while the 1 year total shareholder...

With a price-to-earnings (or "P/E") ratio of 5x COSCO SHIPPING Holdings Co., Ltd. ( HKG:1919 ) may be sending very...

Key Insights Significant insider control over SAINT BELLA implies vested interests in company growth A total of 3...

Key Insights Shenghui Cleanness Group Holdings' significant insider ownership suggests inherent interests in company's...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 13x, you may consider...

The last three months have been tough on Viva Biotech Holdings ( HKG:1873 ) shareholders, who have seen the share price...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Flydoo Technology Holding Limited's ( HKG:8069 ) price-to-sales (or "P/S") ratio of 0.1x may look like a pretty...

It's nice to see the HG Semiconductor Limited ( HKG:6908 ) share price up 11% in a week. But that doesn't change the...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...

From what we can see, insiders were net buyers in Consun Pharmaceutical Group Limited's ( HKG:1681 ) during the past 12...

Smart-Core Holdings Limited ( HKG:2166 ) shareholders have had their patience rewarded with a 33% share price jump in...

When close to half the companies operating in the Media industry in Hong Kong have price-to-sales ratios (or "P/S...

It's not a stretch to say that China Petroleum & Chemical Corporation's ( HKG:386 ) price-to-earnings (or "P/E") ratio...

In late 2025, Alphamab Oncology’s board announced that China’s Center for Drug Evaluation had accepted its Investigational New Drug application for a phase II trial of JSKN033, a high-concentration subcutaneous co-formulation combining a HER2-targeting bispecific ADC and a PD-L1 inhibitor with platinum-based chemotherapy, with or without bevacizumab, in advanced cervical cancer. This acceptance marks a key progression in Alphamab Oncology’s immuno-oncology pipeline, highlighting its effort...

Geely Automobile Holdings (SEHK:175) is back in focus after using CES 2026 to showcase its Full-Domain AI 2.0 vehicle intelligence architecture and the G-ASD smart driving system, along with expansion plans for its Zeekr brand in Europe. See our latest analysis for Geely Automobile Holdings. Despite the CES 2026 headlines and strong 2025 delivery update, the recent share price momentum has softened, with a 7 day share price return of 5.55% and a 90 day share price return of 9.76%, while the 1...

In late 2025, China Resources Gas Group announced a New Framework Agreement under which CR Gas Chenzhou will install and maintain energy meters and supply integrated energy, including natural gas decentralized energy and multiple thermal energy, supported by strengthened internal controls overseen by its financial, legal, audit and internal audit departments. A distinctive feature of this agreement is the layered oversight by independent non-executive directors and external auditors, aiming...